Athenex phase 1 neuroblastoma candidate trial hit by patient death; down 28%

Stock Information for Athenex Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Athenex Inc.

Athenex, Inc. Reaches Agreement With Lenders to Pursue Expedited Sales Process
Quantum Leap Healthcare Collaborative Announces Result of Oral Paclitaxel in Combination with a PD-1 and Carboplatin from I-SPY2 TRIAL at ASCO
Athenex Provides Fourth Quarter and Full Year 2022 Financial Results and Business Update
Athenex Announces a Reverse Stock Split
Athenex Announces MHRA Decision on Oral Paclitaxel
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Athenex Exits 503B Sterile Compounding Business
Athenex Announces Positive Results of Special Stockholder Meeting

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.